Herpes simplex Virus 1 and 2 IgM ELISA Kit

Name: Herpes simplex Virus 1 and 2 IgM ELISA Kit
SKU: DEIA-NS2401-14
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma or cerebrospinal fluid

Species Reactivity

Human

Detection Method

iELISA

Intended Use

ELISA Herpes Simplex Virus Type 1 and 2 IgM are quantitative and qualitative tests for detection of human antibodies in serum, plasma or cerebrospinal fluid against Herpes Simplex Virus (HSV). With HSV 1 IgG and HSV 2 IgG, differentiation between human Herpes Simplex Virus 1 and Herpes Simplex Virus 2 antibodies is possible. For sale in the U.S. for Research Use Only. Not for use in diagnostic procedures.

Contents of Kit

1. Break apart microtiter test strips each with 8 antigen coated single wells (altogether 96), 1 frame, the coating material is inactivated, 12
2. Standard serum (ready-to-use), Human serum in phosphate buffer with protein; negative for antiHIV-Ab, anti-HBs-Ag (Hepatitis B-Virus-surface antigen) and anti HCV-Ab; preservative: < 0.1 % sodium azide, coloring: Amaranth O. 2 × 2 ml
3. Negative control serum (ready-to-use), Human serum in phosphate buffer with protein; negative for anti HIV, anti-HBs (Hepatitis B-Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide, coloring: Lissamin green V . 2 ml
4. Anti-human-IgM-conjugate (ready-to-use), Anti-human-IgM from goat (polyclonal), conjugated to alkaline phosphatase, stabilized with protein stabilization solution preservative: 0.01 % methylisothiazolone, 0.01 % bromnitrodioxane.13 ml.
5. Washing solution concentrate (sufficient for 1 litre), Sodium chloride solution with Tween 20, 30 mM Tris, preservative: < 0.1 % sodium azide. 33.3 ml
6. Dilution buffer, Phosphate buffer with protein and Tween 20; preservative: < 0.1 % sodium azide, 0.01 g/l Bromphenol blue sodium salt. 2 × 50 ml
7. Stopping solution, 1.2 N sodium hydroxide. 15 ml
8. Substrate (ready-to-use), Para-nitrophenylphosphate, solvent free buffer, preservative: < 0.1 % sodium azide. (Substrate in unopened bottle may have a slightly yellow coloring. This does not reduce the quality of the product!) 13 ml

Storage

Reagent	Storage	Stability
microtiter strips (antigen)	after opening at 2-8°C in closed aluminum bag with desiccant. Strips which are not used must be stored in the press-seal bag of aluminum compound foil under dry and airtight conditions!	4 weeks
control sera / standard sera	after opening at 2-8°C	until expiry date; 24 months from date of production
conjugate	ready-to-use solution, at 2-8°C, Avoid contamination (sterile tips!)	until expiry date 28 months from date of production
washing solution	concentrate after opening at 2-8°C; working dilution at 2-8°C; working dilution at room temperature. Bottles used for the working dilution should be cleaned regularly, discard cloudy solutions.	until expiry date; 2 weeks; 1 week
dilution buffer	after opening at 2-8°C, Discard cloudy solutions!; unopened	24 months; until expiry date; 36 months from date of production
substrate	ready-to-use solution at 2-8°C, protected from light! Avoid contamination (sterile tips!) Discard when solution turns yellow (extinction against distilled water > 0.25).	until expiry date 24 months from date of production
stopping solution	after opening at room temperature	until expiry date

General Description

Herpes Simplex Virus 1 (HSV1) and Herpes Simplex Virus 2 (HSV2) are human pathogen DNA viruses belonging to the family of Herpesviridae.
Herpes viruses are globally spread. Primary infection can be caused by contact with infected persons (saliva or urogenital secretion), cross-placentally or iatrogenically through transfusions or transplantations. After primary infection, local ganglions show lifelong virus persistence, enabling the reactivation of latent infections.
The transmission of Herpes genitalis during delivery can progress subclinically. In most cases it leads to localized or disseminated sepsis-like diseases.
After primary infection, viruses persist in certain cell types (latent cycle) until reactivation (lytic cycle). Reactivation occasionally progresses without symptoms or with low pathology in immunocompetent persons whereas severe clinical complications occur in immunocompromised patients.

Citations